Wuhan Institute of Biological Products Co., Ltd (WIBP), founded in September, 1950, is affiliated to China National Biotec Group Company Limited (CNBG), which is a subsidiary of Sinopharm, a centrally-administered State-owned enterprise under the direct management of the State-owned Assets Supervision and Administration Commission of the State Council. It is a large-scale high-tech enterprise integrating production, education, development and marketing of biological products, and one of the major biological products manufacturing bases in China, shouldering the responsibility of vaccine development and production to meet the needs of Chinese people’s health.

　　WIBP covers an area of 542 mu (361,335m2),with a registered capital of 2.764 billion yuan (around 3.83 million dollars), total assets exceeding 10 billion yuan (around 1.39 billion dollars), more than 1,300 employees and a subsidiary named Yujin Bio-pharma Wuhan CNBG Co., Ltd. It is one of the first doctoral and master's degree awarding units entitled by the State Counsel, and it has the sole doctoral program in the biological products industry. In 2010, it established a post-doctoral research center. During the past years, it has trained a large number of senior biotechnology talents for the biological products industry.

　　WIBP is committed to the development of biopharmaceutical industry in the spirit of unity, enterprise, pragmatism and innovation, and strives to make due contributions to human health. Taking “All for health, health for all” as the company philosophy, and “Product quality is the lifeblood of the enterprise, the product users are our family members.” as the quality policy, WIBP conducts quality management in strict accordance with the requirements of regulations such as Chinese Pharmacopoeia and Good Manufacturing Practice, and has established a sound quality management system. All the existing facilities of the leading products are GMP certified by the regulatory authorities, with advanced equipment and facilities, cutting-edge technology and first-class product quality.

　　WIBP not only finishes the task of developing and manufacturing the NIP vaccines, but also devotes itself to the development of innovative biological products. It has strong strength and rich experience in the transformation and industrialization of product achievements. At present, it has formed four sections: vaccines for human use, therapeutic products, diagnostic reagents and technical services, with more than 60 production licenses, 5 of which are for NIP vaccines. ranking first in number of categories in China. WIBP supplies 10 products on the market, including Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed; Japanese Encephalitis Vaccine, Live; Enterovirus 71 Vaccine （Vero Cell), Inactivated; Group A Meningococcal Polysaccharide Vaccine; Diphtheria and Tetanus Combined Vaccine, Adsorbed; Tetanus Vaccine, Adsorbed; Leptospira Vaccine; Typhoid Vi Polysaccharide Vaccine and Anti-human T Cell Porcine Immunoglobulin, etc., with a total annual production capacity of over 120 million doses.

　　WIBP has four ministerial-level scientific and technological innovation and industrialization platforms, namely National Combination Vaccine Technology Research Center, National and Local Joint Research Center for Biological Products, National Enterprise Technology Center and National Technological Innovation Demonstration Enterprise. It has been supported by scientific research projects such as the National "863 Plan", "Major New Drug Development", "National Science and Technology Support Plan", Vaccine Project of the National Development and Reform Commission and the Key Research Projects of Hubei Province and Wuhan City, and has completed the development of a number of new products, and made significant progress in scientific and technological innovation, among which Enterovirus 71 Vaccine （Vero Cell), Inactivated, Influenza Vaccine (Split Virion), Inactivated, and Quadrivalent, COVID-19 Vaccine, Inactivated have been approved for marketing or conditionally approved, and won a series of national, provincial and municipal achievement awards and scientific and technological progress awards.

　　In the fight against COVID-19 pandemic, WIBP actively carried out a series of urgent scientific and technological research, including the development of inactivated COVID-19 vaccine, convalescent plasma therapy for COVID-19 and development of monoclonal antibody against COVID-19, etc., covering all the 3 fields of diagnosis, treatment and prevention at the same time. It was the first Chinese biopharmaceutical enterprise whose COVID-19 vaccine and therapeutic products agaisnt COVID-19 have been approved for clinical use, which contributed to the global fight against COVID-19 pandemic.

　　Under the unified leadership of Sinopharm, WIBP will realize the modernization of enterprise management, the professionalization of talent team, the internationalization of product market, the automation of production facilities and the gardenization of campus environment, and strive to become an excellent enterprise within Sinopharm, an advanced enterprise in the industry and an enterprise with international influence.